What Zhenao Pharmaceutical Group does

Zhenao Pharmaceutical Group (真奥药业集团) is a privately held traditional Chinese medicine (TCM) pharmaceutical group headquartered in Xianning, Hubei Province, China, founded in 2019. The company operates an integrated value chain spanning medicinal herb cultivation, pharmaceutical R&D, manufacturing, marketing, and downstream healthcare services. It owns five wholly-owned production bases — Zenao Honeysuckle Pharmaceutical (Hubei), Shanxi Zhenglai Pharmaceutical, Harbin Hanjun Modern Pharmaceutical, Chifeng Weikang Pharmaceutical, and Hebei Baishan Pharmaceutical — together with over 30 production lines, more than 300 SKUs, and 60+ patented technologies. The group also operates Shangjing Hospital, a large private general hospital in Inner Mongolia.

The company's flagship product is 药舖小神仙® Honeysuckle Oral Liquid (金银花口服液), which holds a 65.29% market share within Chinese honeysuckle preparations and was ranked the #1 single product in the category in 2023; clinical research presented at the 5th China Integrative Medicine Respiratory Disease Academic Symposium supports its use in COVID-19 lung function improvement and viral nucleic acid conversion acceleration. Its second key product, 正来潞党® Codonopsis Oral Liquid (潞党参口服液), has documented RCT evidence in COVID-19 recovery symptom improvement (shortness of breath, fatigue, sleep, quality of life). The broader portfolio spans respiratory, digestive, pediatric, cardiovascular, and pain management categories under sub-brands including 药舖小神仙, 正来潞党, 百善为民/健者, 妙存, and 贝乐芬.

Zhenao generates revenue through pharmaceutical product sales across two primary go-to-market motions: a clinical/academic sales force covering regional clinical managers, recruitment managers, and academic promotion specialists positioned across 11+ major Chinese cities, and an OTC retail pharmacy channel with provincial managers and terminal reps executing a "retail academic" strategy. The retail academic model is anchored by a strategic partnership with China Pharmacy (中国药店), delivering the Gold Medal Chinese Medicine Pharmacist training series and the "Little Red Umbrella Action" public welfare campaign launched June 2024. End customers include public medical institutions, retail pharmacy chains, and consumers; pricing is not publicly disclosed. The company is preparing for a domestic IPO, having been listed on the Hubei Province 2024-2025 IPO Reserve Gold Seed Enterprise list.

Name

Zhenao Pharmaceutical Group

Legal name

真奥药业集团有限公司

Website

https://zayyjt.com

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Zhenao Pharmaceutical Group is a privately held traditional Chinese medicine company founded in 2019 in Hubei, China, operating five production bases and a hospital. It manufactures and distributes TCM formulations — led by Honeysuckle Oral Liquid with 65.29% category share — through clinical sales and OTC pharmacy channels.

Ownership category

akta.pro rank

Product category

Traditional Chinese Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Traditional Chinese medicine
• Pharmaceutical manufacturing
• Herbal formulations
• OTC drug distribution
• Respiratory therapeutics

Headquarters

HQ city

Hubei

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Zhenao Pharmaceutical generates revenue through the sale of pharmaceutical products across multiple therapeutic areas including respiratory, digestive, pediatric, and cardiovascular medicine. The company operates five production bases and distributes through clinical/academic sales channels and retail pharmacy chains.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Zhenao Pharmaceutical Group is an integrated pharmaceutical manufacturer and healthcare services provider specializing in Traditional Chinese Medicine (TCM) formulations across five production bases and one private hospital. The company manufactures oral liquids, tablets, capsules, and granules for respiratory, digestive, pediatric, and cardiovascular therapeutic areas, with flagship Honeysuckle Oral Liquid commanding 65.29% market share in its category. The group distributes products through clinical sales to public medical institutions and through retail pharmacy chains (OTC) to end consumers, complemented by Shangjing Hospital healthcare services in Inner Mongolia.

Product overview

Zhenao Pharmaceutical Group operates a multi-brand pharmaceutical portfolio across five production bases (真奥金银花药业, 山西正来制药, 哈尔滨瀚鈞现代制药, 河北百善药业, 赤峰维康制药) plus 上京医院. The company specializes in traditional Chinese medicine products including core offerings like 药舖小神仙®金银花口服液 (which holds 65.29% market share in honeysuckle preparations), 正来潞党®潞党参口服液, and various other TCM formulations spanning oral liquids, tablets, capsules, and granules for respiratory, digestive, pediatric, and cardiovascular health applications.

Differentiator

Problem solved

Functional benefit

Brands

• 药舖小神仙: Brand for Jin Yinhua (金银花) oral liquid product line
• 正来潞党
• 百善为民/健者
• 妙存
• 贝乐芬

Products and services

• Yaopu Xiaoshenxian® Honeysuckle Oral Liquid (药舖小神仙®金银花口服液) Traditional Chinese medicine oral liquid for clearing heat and detoxifying, used for treating heat-related symptoms, respiratory infections, and demonstrated clinical effectiveness in COVID-19 treatment including improved lung function, shortened hospital stay, and accelerated viral nucleic acid conversion.
• Zhenglai Ludang® Ludang Ginseng Oral Liquid (正来潞党®潞党参口服液) Traditional Chinese medicine oral liquid containing Codonopsis (党参), used for strengthening the spleen and improving digestive function. RCT study demonstrates effectiveness in improving clinical symptoms in COVID-19 recovery patients, including shortness of breath, activity capacity, fatigue, quality of life, and psychological/sleep conditions, showing a dose-response relationship.
• Miaocun® Lecithin Tablets (妙存®卵磷脂片) Lecithin supplement tablets for supporting cardiovascular health and cellular function, distributed under the Miaocun brand.
• Baishan Weimin® Jianzhe® Ginseng Spleen Tablets (百善为民®健者®人参健脾片) Traditional Chinese medicine tablets containing ginseng for strengthening the spleen and improving digestive function.
• Beilefen® Ibuprofen Dispersible Tablets (贝乐芬®布洛芬分散片) Ibuprofen dispersible tablets for pain relief and anti-inflammatory treatment, produced by Chifeng Weikang Pharmaceutical.
• Zhikejuhao® Yumei Dispersible Tablets (止刻句号®愈美分散片) Compound cough relief and expectorant dispersible tablets for respiratory conditions.
• Tefengping® Xizhi Luoda Capsules (特风平®蝮蚣络达胶囊) Traditional Chinese medicine capsules for rheumatic conditions and joint health.
• Xiaohoushi® Mumu® Spleen-Stomach Granules (小时候®沐沐®健脾养胃颗粒) Traditional Chinese medicine granules designed for children's digestive health and spleen strengthening.
• Jiaxun® Ferrous Fumarate and Docusate Sodium Capsules (佳迅®富马酸亚铁多库酯钠胶囊) Iron supplement capsules for treating iron deficiency anemia.
• Jingyixin® Clonidine Patch (晶亦新®可乐定贴片) Transdermal clonidine patch for hypertension management.
• Xinfang Zengli® Tongxuan Lifei Granules (新方增力®通宣理肺颗粒) Traditional Chinese medicine granules for relieving cough and expelling phlegm.
• Zhenglai® Compound Ganoderma Brain Capsules (正来®复方灵芝健脑胶囊) Traditional Chinese medicine capsules containing Ganoderma (lingzhi mushroom) for brain health and cognitive function.
• Cong'ergao® Zhiqi Granules (聪而高®智杞颗粒) Traditional Chinese medicine granules for children's cognitive development and intelligence support.
• Shangjing Hospital (上京医院) Healthcare Services Large private comprehensive hospital in Inner Mongolia region providing general medical services as part of the group's integrated healthcare services vertical, recognized as a China Integrity Demonstration Hospital and National Cardiovascular Disease Center Hypertension Medical Alliance member.

Quantifiable outcome

• 金银花口服液在常规治疗基础上可有效改善新型冠肺炎患者肺部功能，缩短住院天数、病毒核酸转阴时长，安全性高
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• 中国药店 (China Pharmacy)coreStrategic or Co-development PartnerStrategic partnership for 'retail academic' marketing. Zhenao partners with China Pharmacy to conduct Gold Medal Chinese Medicine Pharmacist series activities, providing professional training and certification programs for retail chain partners. This partnership helps extend brand influence from product level to health communication, public welfare, and social value.
• 中国中药协会 (China Association of Chinese Medicine)coreStrategic or Co-development PartnerZhenao Pharmaceutical participates in academic conferences organized by China Association of Chinese Medicine, including the 5th China Integrative Medicine Respiratory Disease Academic Seminar. The company presented clinical research on 金银花口服液 and 潞党参口服液, gaining expert recognition and the 'Innovation Excellence Award'.
• 湖北中医药大学 (Hubei University of Chinese Medicine)coreStrategic or Co-development PartnerZhenao Pharmaceutical has established internship base and graduate workstation partnerships with Hubei University of Chinese Medicine, supporting talent development and research collaboration.
• 湖北工业大学 (Hubei University of Technology)coreStrategic or Co-development PartnerZhenao Pharmaceutical has established internship base and graduate workstation partnerships with Hubei University of Technology for talent development and research collaboration.
• 零售药店连锁 (Retail Pharmacy Chains)coreChannel Partner/ Reseller/ DistributorZhenao Pharmaceutical partners with retail pharmacy chains through their 'Little Red Umbrella Action' initiative, implementing public welfare programs including sanitation worker care umbrellas and pharmacy convenience umbrellas. The company provides training and marketing support through their 'retail academic' strategy.
• 上京医院 (Shangjing Hospital)coreOthersShangjing Hospital is a wholly-owned subsidiary of Zhenao Pharmaceutical Group, providing comprehensive medical services as a large private comprehensive hospital in Inner Mongolia region.
• 协和江南医院 (Union Jiangnan Hospital / Wuhan Jiangxia District First People's Hospital)coreStrategic or Co-development PartnerDr. Hu Fen from Union Jiangnan Hospital presented clinical research on '金银花口服液 combined with Western medicine for COVID-19 treatment', demonstrating the product's effectiveness in improving lung function and shortening hospital stay. The hospital conducted a multi-center clinical observation study.
• 中国中医科学院广安门医院 (Guang'anmen Hospital, China Academy of Chinese Medical Sciences)coreStrategic or Co-development PartnerDr. Bian Yongjun from Guang'anmen Hospital presented research on '潞党参口服液 for COVID-19 recovery phase digestive function decline RCT study', confirming the product's effectiveness in improving clinical symptoms in recovering COVID-19 patients.
• 南开大学 (Nankai University)minorStrategic or Co-development PartnerProfessor Bai Gang from Nankai University presented the latest research findings on honeysuckle oral liquid, explaining the anti-inflammatory, antipyretic mechanisms of active ingredients swertiamarin and chlorogenic acid.
• 五家药品生产基地 (Five Pharmaceutical Production Bases)coreOthersZhenao Pharmaceutical Group operates five pharmaceutical production bases: 真奥金银花药业, 山西正来制药, 哈尔滨瀚鈞现代制药, 赤峰维康制药, and 河北百善药业. These are wholly-owned subsidiaries within the group structure.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Zhenbaodao Pharmaceutical (珍宝岛药业): Chinese TCM company focused on injectable and oral TCM formulations, with growing clinical/academic promotion. Comparable in TCM product mix and marketing approach targeting respiratory and cardiovascular segments.
• Buchang Pharmaceutical (步长制药): Mid-cap Chinese TCM company with diversified product portfolio across cardiovascular, respiratory, and digestive health, distributed through clinical and retail channels. Closely comparable in therapeutic mix and channel strategy.
• Yiling Pharmaceutical (以岭药业): A leading Chinese TCM innovator with strong clinical/academic promotion, respiratory franchises, and patented formulations. Comparable to Zhenao in using RCT evidence and clinical sales force to monetize TCM products in the respiratory/cardiovascular space.
• China TCM Holdings (中国中药控股): Major Chinese TCM manufacturer and distributor with vertically integrated operations from herb cultivation to finished dosage forms. Comparable in integrated industrial chain model spanning multiple production bases and product categories.
• Shineway Pharmaceutical (神威药业): Major Chinese TCM manufacturer with multi-category portfolio including respiratory, pediatric, and cardiovascular products. Comparable in production capacity, SKU breadth, and clinical/retail dual-channel distribution.
• Kangyuan Pharmaceutical (康缘药业): Chinese TCM pharmaceutical company with strong R&D focus and clinical-academic promotion of innovative TCM formulations. Comparable in targeting respiratory/gynecological/spleen-stomach indications with patented formulations.

Broad incumbents

• Tongrentang (同仁堂): China's most iconic traditional Chinese medicine brand with centuries of heritage and a vast product portfolio. A much larger competitor offering broader brand recognition and deeper pharmacy distribution nationwide.
• Yunnan Baiyao (云南白药): China's largest TCM company offering branded TCM products, OTC healthcare, and pharmaceutical distribution. Represents the scale ceiling and brand-led competitive dynamic Zhenao competes against.
• Guangzhou Baiyunshan (广药白云山): Large Chinese pharmaceutical conglomerate with extensive TCM and Western medicine portfolio. A broader incumbent with deeper capital resources and distribution across retail pharmacy chains.

Regional players

• Kangmei Pharmaceutical (康美药业): Chinese TCM company historically focused on medicinal materials cultivation, TCM manufacturing, and pharmacy distribution. Comparable in vertical integration from herb cultivation to finished products.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhenao Pharmaceutical Group